These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 16459330)

  • 1. Oncostatin M receptor-mediated signal transduction is negatively regulated by SOCS3 through a receptor tyrosine-independent mechanism.
    Stross C; Radtke S; Clahsen T; Gerlach C; Volkmer-Engert R; Schaper F; Heinrich PC; Hermanns HM
    J Biol Chem; 2006 Mar; 281(13):8458-68. PubMed ID: 16459330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contributions of leukemia inhibitory factor receptor and oncostatin M receptor to signal transduction in heterodimeric complexes with glycoprotein 130.
    Hermanns HM; Radtke S; Haan C; Schmitz-Van de Leur H; Tavernier J; Heinrich PC; Behrmann I
    J Immunol; 1999 Dec; 163(12):6651-8. PubMed ID: 10586060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncostatin M regulates SOCS3 mRNA stability via the MEK-ERK1/2-pathway independent of p38(MAPK)/MK2.
    Ehlting C; Böhmer O; Hahnel MJ; Thomas M; Zanger UM; Gaestel M; Knoefel WT; Schulte Am Esch J; Häussinger D; Bode JG
    Cell Signal; 2015 Mar; 27(3):555-67. PubMed ID: 25562430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Key role of suppressor of cytokine signaling 3 in regulating gp130 cytokine-induced signaling and limiting chondrocyte responses during murine inflammatory arthritis.
    Liu X; Croker BA; Campbell IK; Gauci SJ; Alexander WS; Tonkin BA; Walsh NC; Linossi EM; Nicholson SE; Lawlor KE; Wicks IP
    Arthritis Rheumatol; 2014 Sep; 66(9):2391-402. PubMed ID: 24839265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SHP2 and SOCS3 contribute to Tyr-759-dependent attenuation of interleukin-6 signaling through gp130.
    Lehmann U; Schmitz J; Weissenbach M; Sobota RM; Hortner M; Friederichs K; Behrmann I; Tsiaris W; Sasaki A; Schneider-Mergener J; Yoshimura A; Neel BG; Heinrich PC; Schaper F
    J Biol Chem; 2003 Jan; 278(1):661-71. PubMed ID: 12403768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of SOCS3 phosphorylation upon interleukin-6 stimulation. Contributions of Src- and receptor-tyrosine kinases.
    Sommer U; Schmid C; Sobota RM; Lehmann U; Stevenson NJ; Johnston JA; Schaper F; Heinrich PC; Haan S
    J Biol Chem; 2005 Sep; 280(36):31478-88. PubMed ID: 16000307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Receptor subunit-specific action of oncostatin M in hepatic cells and its modulation by leukemia inhibitory factor.
    Wang Y; Robledo O; Kinzie E; Blanchard F; Richards C; Miyajima A; Baumann H
    J Biol Chem; 2000 Aug; 275(33):25273-85. PubMed ID: 10854424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Box 2 region of the oncostatin M receptor determines specificity for recruitment of Janus kinases and STAT5 activation.
    Hintzen C; Evers C; Lippok BE; Volkmer R; Heinrich PC; Radtke S; Hermanns HM
    J Biol Chem; 2008 Jul; 283(28):19465-77. PubMed ID: 18430728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Constitutive suppressor of cytokine signaling 3 expression confers a growth advantage to a human melanoma cell line.
    Komyod W; Böhm M; Metze D; Heinrich PC; Behrmann I
    Mol Cancer Res; 2007 Mar; 5(3):271-81. PubMed ID: 17374732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential inhibition of IL-6-type cytokine-induced STAT activation by PMA.
    Terstegen L; Maassen BG; Radtke S; Behrmann I; Schaper F; Heinrich PC; Graeve L; Gatsios P
    FEBS Lett; 2000 Jul; 478(1-2):100-4. PubMed ID: 10922477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Signal transduction of IL-6, leukemia-inhibitory factor, and oncostatin M: structural receptor requirements for signal attenuation.
    Anhuf D; Weissenbach M; Schmitz J; Sobota R; Hermanns HM; Radtke S; Linnemann S; Behrmann I; Heinrich PC; Schaper F
    J Immunol; 2000 Sep; 165(5):2535-43. PubMed ID: 10946280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stimulation of the JAK/STAT pathway by LIF and OSM in the human granulosa cell line COV434.
    Pastuschek J; Poetzsch J; Morales-Prieto DM; Schleußner E; Markert UR; Georgiev G
    J Reprod Immunol; 2015 Apr; 108():48-55. PubMed ID: 25817464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130.
    Schmitz J; Weissenbach M; Haan S; Heinrich PC; Schaper F
    J Biol Chem; 2000 Apr; 275(17):12848-56. PubMed ID: 10777583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Negative regulation of gp130 signalling mediated through tyrosine-757 is not dependent on the recruitment of SHP2.
    Fairlie WD; De Souza D; Nicola NA; Baca M
    Biochem J; 2003 Jun; 372(Pt 2):495-502. PubMed ID: 12593670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The tyrosine 974 within the LIF-R-chain of the gp130/LIF-R heteromeric receptor complex mediates negative regulation of LIF signalling.
    Clahsen T; Lehmann U; Stross C; Hermanns HM; Volkmer-Engert R; Schneider-Mergener J; Heinrich PC; Schaper F
    Cell Signal; 2005 May; 17(5):559-69. PubMed ID: 15683731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Signaling of type II oncostatin M receptor.
    Auguste P; Guillet C; Fourcin M; Olivier C; Veziers J; Pouplard-Barthelaix A; Gascan H
    J Biol Chem; 1997 Jun; 272(25):15760-4. PubMed ID: 9188471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of subunit combinations on signaling by receptors for oncostatin M, leukemia inhibitory factor, and interleukin-6.
    Kuropatwinski KK; De Imus C; Gearing D; Baumann H; Mosley B
    J Biol Chem; 1997 Jun; 272(24):15135-44. PubMed ID: 9182534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncostatin M-induced activation of stress-activated MAP kinases depends on tyrosine 861 in the OSM receptor and requires Jak1 but not Src kinases.
    Böing I; Stross C; Radtke S; Lippok BE; Heinrich PC; Hermanns HM
    Cell Signal; 2006 Jan; 18(1):50-61. PubMed ID: 15935618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation.
    Mosley B; De Imus C; Friend D; Boiani N; Thoma B; Park LS; Cosman D
    J Biol Chem; 1996 Dec; 271(51):32635-43. PubMed ID: 8999038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OSM/OSMR and Interleukin 6 Family Cytokines in Physiological and Pathological Condition.
    Lantieri F; Bachetti T
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.